Shanghai Rightongene Biotechnology (688217)2025-01-17 09:30Revenue Projections - The company expects 2024 annual revenue to be between 238 million and 245 million yuan, representing a year-on-year decrease of 5.12% to 7.83% compared to 258 million yuan in 2023[3]. - In Q1 2024, the company's revenue increased by 12.84% year-on-year, but Q3 saw a decline of 23.04% due to unexpected events affecting product admission progress[6]. Profit and Loss Forecast - The projected net loss attributable to the parent company for 2024 is between 11.29 million and 16.94 million yuan, a significant decline from a net profit of 7.93 million yuan in 2023[3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be between -14.80 million and -20.44 million yuan for 2024[3]. Expenses and Impairments - The company incurred additional depreciation and amortization expenses of 1.04 million yuan due to new facilities coming online in 2023, along with legal consulting fees of 4.51 million yuan arising from unexpected events[6]. - The company recognized a credit impairment loss of 9.32 million yuan on accounts receivable, an increase of 3.80 million yuan compared to the previous year, due to slower customer payments in a sluggish medical industry[6]. - A goodwill impairment of 14.30 million yuan was recorded, which is an increase of 6.81 million yuan from the previous year, attributed to underperformance of subsidiaries in the medical sector[6]. Financial Data Disclaimer - The company emphasizes that the financial data provided is preliminary and has not been audited by external accountants, urging investors to be cautious[7][8].